Crescent Biopharma/$CBIO

1D1W1MYTD1Y5YMAX

About Crescent Biopharma

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Ticker
$CBIO
Sector
Health
Primary listing
NASDAQ
Employees
69
Headquarters
Waltham, United States
Website
crescentbiopharma.com

CBIO Metrics

BasicAdvanced
$599M
-
-$6.03
-
-

Bulls say / Bears say

CR-001 has moved into the global ASCEND Phase 1/2 trial, with enrolment progressing across several solid tumours and proof-of-concept data due in the first quarter of 2027. That gives CBIO a clear near-term clinical catalyst and a chance to test the bispecific in both monotherapy and chemotherapy combinations. (Crescent Biopharma, RTT News)
The company is building more than a single-asset story: CR-003 is already in a Phase 1/2 trial in China, while the global CR-002 trial is targeted to start in the second half of 2026. Positive results from any of the three assets, or from planned CR-001 and ADC combinations, could materially broaden the opportunity. (Crescent Biopharma, StockAnalysis)
CBIO raised approximately $143.7 million in a July public offering, and management says the proceeds extend its expected cash runway into the second half of 2028. That should allow the company to fund several upcoming readouts without needing an immediate financing round. (Crescent Biopharma, Crescent Biopharma)
CR-001 remains an early-stage, unapproved medicine, so its attractive preclinical comparisons with ivonescimab still need to translate into human safety and efficacy. The first meaningful proof-of-concept readout is not expected until the first quarter of 2027. (StockAnalysis, Crescent Biopharma)
CBIO has no established product revenue and is funding several costly clinical programmes; its second-quarter net loss was $24.8 million. The July share and pre-funded-warrant offering also expanded the equity base, so further development could bring more dilution if spending outlasts the current runway. (StockTitan, Crescent Biopharma)
The portfolio still depends on difficult execution across several studies and partners, with key CR-003 and CR-001 combination data largely scheduled for 2027. Management itself says CR-001 must demonstrate safety, tolerability, pharmacokinetics and antitumour activity before it can justify accelerated later-stage development, leaving substantial clinical and timing risk. (StockAnalysis, RTT News)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.

Funds containing CBIO

Funds
Fund name
Fund size
$CBIO weighting
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.